Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs JD.Com Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.25 (market cap $29.60B), while JD.Com Inc trades at $31.32 (market cap $44.04B). The key difference: JD.Com Inc is the larger of the two by market cap, and JD.Com Inc pays a 3.13% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | JD | |
|---|---|---|
Market Cap | $29.60B | $44.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $36.17 |
52-Week Low | $205.48 | $25.19 |
Enterprise Value | $27.56B | $30.10B |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
JD stock trades at $31.29, down 6.51% over 24 hours, amid broader pressure on Chinese equities. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue grew to $1.31 trillion in 2025. Technical indicators show a bullish overall signal, with RSI at 28.66 suggesting potential oversold conditions. Analyst consensus remains strongly bullish with a $38.00 price target.
The outlook is positive given earnings beats and low valuation multiples like P/S of 0.24, but risks include regulatory scrutiny from the EU over the Ceconomy deal and margin pressures from expansion costs. Upside potential exists if Q2 results on August 13, 2026, exceed expectations, though macroeconomic headwinds for Chinese stocks pose a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
